Abstract Development of the retinal vasculature is based on highly coordinated signalling
between different cell types of the retina, integrating internal metabolic requirements with …

Background Vascular endothelial growth factor (VEGF) plays a key role in angiogenesis in
foetal life. Researchers have recently attempted to use anti‐VEGF agents for the treatment of …

Background Despite increasing worldwide use of anti-vascular endothelial growth factor
agents for treatment of retinopathy of prematurity (ROP), there are few data on their ocular …

The incidence of retinopathy of prematurity (ROP) continues to rise due to the improved
survival of very low birth weight infants in developed countries. This epidemic is also fueled …

The population of infants at risk for retinopathy of prematurity (ROP) varies by world region;
in countries with well developed neonatal intensive care services, the highest risk infants are …

OBJECTIVE: Among extremely preterm infants, we evaluated whether bevacizumab therapy
compared with surgery for retinopathy of prematurity (ROP) is associated with adverse …

Background Infants with stage 3+ retinopathy of prematurity (ROP) in zone I or zone II
posterior were randomized to initial treatment with bevacizumab or laser in a multicenter trial …

Although intravitreal injection of anti-vascular endothelial growth factor agents (IVA) can
induce rapid regression of retinopathy of prematurity (ROP), late reactivation of the ROP can …

Retinopathy of prematurity (ROP) is a neurovascular disease that affects prematurely born
infants and is known to have significant long term effects on vision. We conducted the …

Background Retinopathy of prematurity (ROP) is typically treated with laser
photocoagulation and/or intravitreal anti-vascular endothelial growth factor (anti-VEGF). To …